MALVERN, Pa.--(BUSINESS WIRE)--After careful consideration, the Board of Trustees of Pacer Funds Trust has determined to close and liquidate the Pacer BioThreat Strategy ETF (VIRS) and the Pacer CSOP FTSE China A50 ETF (AFTY). Pacer Advisors, Inc. (“Pacer Advisors”) serves as the investment adviser to each Fund.
Effective on or about September 27, 2024, each Fund will begin liquidating its portfolio assets. This will cause each Fund to increase its cash holdings and deviate from the investment objectives and strategies stated in each Fund’s prospectus. The Funds will no longer accept orders for new creation units after the close of business on the business day prior to October 11, 2024 (the “Liquidation Date”), and trading in shares of each Fund will be halted prior to market open on the Liquidation Date. Prior to the Liquidation Date, shareholders may only be able to sell their shares to certain broker-dealers, and there is no assurance that there will be a market for each Funds’ shares during that time period. Customary brokerage charges may apply to such transactions.
On or about the Liquidation Date, each Fund will liquidate its assets and distribute cash pro rata to all remaining shareholders. These distributions are taxable events. Shareholders should contact their tax advisor to discuss the income tax consequences of the liquidation. In addition, these payments to shareholders will include accrued capital gains and dividends, if any. As calculated on the Liquidation Date, each Fund’s net asset value will reflect the costs of closing each Fund, if any. Once the distributions are complete, each Fund will terminate. Proceeds of the liquidation will be sent to shareholders promptly after the Liquidation Date.
For additional information, please call 1-800-617-0004.
Before investing you should carefully consider the Fund’s investment objectives, risks, charges, and expenses. This and other information is in the prospectus. A copy may be obtained by visiting https://www.paceretfs.com or calling 1-877-337-0500. Please read the prospectus carefully before investing.
An investment in the Funds is subject to investment risk, including the possible loss of principal. Pacer ETF shares may be bought and sold on an exchange through a brokerage account. Brokerage commissions and ETF expenses will reduce investment returns. There can be no assurance that an active trading market for ETF shares will be developed or maintained. The risks associated with these funds are detailed in the prospectus and could include factors such as risk of investing in China, risk of investments in A-Shares, A-Shares tax risk, risk of investing through Shanghai-Hong Kong Stock Connect, risk of investing in Issuers listed on the ChiNext Board, calculation methodology risk, ETF risks, China concentration risk, emerging markets risk, equity market risk, index calculation methodology risk, index criteria risk, non-diversification, passive investment risk, pharmaceutical companies risk, foreign securities risk, index tracking error risk, large and mid-capitalization investing risk, non-U.S. currency risk, passive investment risk, sector risk, and shares of the fund may trade at prices other than NAV.
Pacer Advisors, Inc. is the fund advisor to AFTY. CSOP Asset Management LTD is the fund sub-adviser to AFTY. CSOP Asset Management LTD is registered as an investment advisor with the SEC.
The LifeSci BioThreat Strategy Index is a trademark of LifeSci Index Partners, LLC (“LSIP”) and has been licensed for use by Pacer Advisors, Inc. The Pacer BioThreat Strategy ETF (CBOE: VIRS) is not sponsored, endorsed, sold or promoted by LifeSci Index Partners, LLC and LSIP makes no representation or warranty regarding the advisability of investing in the Pacer BioThreat ETF.
NOT FDIC INSURED | MAY LOSE VALUE | NOT BANK GUARANTEED
Distributor: Pacer Financial, Inc., member FINRA, SIPC, an affiliate of Pacer Advisors, Inc.
